XTL Biopharmaceuticals Ltd. (XTLB)’s Financial Results Comparing With Rexahn Pharmaceuticals Inc. (NYSEAMERICAN:RNN)

XTL Biopharmaceuticals Ltd. (NASDAQ:XTLB) and Rexahn Pharmaceuticals Inc. (NYSEAMERICAN:RNN) compete with each other in the Biotechnology sector. We will analyze and contrast their institutional ownership, profitability, analyst recommendations, risk, dividends, earnings and valuation.

Earnings and Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
XTL Biopharmaceuticals Ltd. N/A 0.00 1.94M 0.38 5.84
Rexahn Pharmaceuticals Inc. N/A 0.00 14.84M -0.47 0.00

Table 1 demonstrates XTL Biopharmaceuticals Ltd. and Rexahn Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.


Table 2 shows XTL Biopharmaceuticals Ltd. and Rexahn Pharmaceuticals Inc.’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
XTL Biopharmaceuticals Ltd. 0.00% 33.2% 28.8%
Rexahn Pharmaceuticals Inc. 0.00% -119.8% -71.6%


The current Quick Ratio of XTL Biopharmaceuticals Ltd. is 36 while its Current Ratio is 36. Meanwhile, Rexahn Pharmaceuticals Inc. has a Current Ratio of 4.1 while its Quick Ratio is 4.1. XTL Biopharmaceuticals Ltd. is better positioned to pay off its short-term and long-term debts than Rexahn Pharmaceuticals Inc.

Insider & Institutional Ownership

The shares of both XTL Biopharmaceuticals Ltd. and Rexahn Pharmaceuticals Inc. are owned by institutional investors at 4.5% and 4.8% respectively. About 1% of XTL Biopharmaceuticals Ltd.’s share are owned by insiders. Comparatively, insiders own roughly 1.99% of Rexahn Pharmaceuticals Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
XTL Biopharmaceuticals Ltd. -9.84% -7.56% 21.55% 17.02% -16.35% -3.81%
Rexahn Pharmaceuticals Inc. 0% -6.09% -33.33% -42.55% -47.57% -46.53%

For the past year XTL Biopharmaceuticals Ltd.’s stock price has smaller decline than Rexahn Pharmaceuticals Inc.


XTL Biopharmaceuticals Ltd. beats Rexahn Pharmaceuticals Inc. on 7 of the 7 factors.

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical products for the treatment of autoimmune diseases. Its lead drug candidate is hCDR1, a Phase II-ready asset for the treatment of systemic lupus erythematosus and SjogrenÂ’s syndrome. The company also develops recombinant human erythropoietin for the treatment of multiple myeloma patients. XTL Biopharmaceuticals Ltd. has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1. The company was formerly known as Xenograft Technologies Ltd. and changed its name to XTL Biopharmaceuticals Ltd. in July 1995. XTL Biopharmaceuticals Ltd. was founded in 1993 and is headquartered in Raanana, Israel.

Rexahn Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes treatments for cancer. The companyÂ’s clinical stage drug candidates include RX-3117, which is in Phase IIa clinical trial for the treatment of patients with relapsed or refractory pancreatic cancer and advanced bladder cancer; and Supinoxin that is in Phase IIa clinical study to treat patients with metastatic triple negative breast cancer. It is also developing Archexin, which has completed a pilot Phase IIa clinical trial for the treatment of pancreatic cancer; and is in Phase IIa clinical trial to treat patients with metastatic renal cell carcinoma. In addition, the company is involved in developing RX-21101, an N-(2-Hydroxypropyl) methacrylamide-docetaxel-folate, which is in pre-clinical development stage used for the treatment of tumors. Rexahn Pharmaceuticals, Inc. is headquartered in Rockville, Maryland.